Two Sigma Securities LLC Takes Position in Yarrow Bioscience $YARW

Two Sigma Securities LLC purchased a new position in shares of Yarrow Bioscience (NASDAQ:YARW) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 40,697 shares of the company’s stock, valued at approximately $26,000. Two Sigma Securities LLC owned 0.06% of Yarrow Bioscience at the end of the most recent quarter.

Several other large investors have also made changes to their positions in YARW. Rangeley Capital LLC increased its stake in Yarrow Bioscience by 18.1% in the first quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock valued at $71,000 after acquiring an additional 18,064 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of Yarrow Bioscience in the 2nd quarter valued at $29,000. GSA Capital Partners LLP acquired a new stake in shares of Yarrow Bioscience in the 2nd quarter valued at $47,000. XTX Topco Ltd acquired a new stake in shares of Yarrow Bioscience in the 4th quarter valued at $46,000. Finally, Geode Capital Management LLC increased its stake in shares of Yarrow Bioscience by 64.2% in the 4th quarter. Geode Capital Management LLC now owns 225,152 shares of the company’s stock valued at $131,000 after purchasing an additional 88,030 shares during the last quarter. Institutional investors and hedge funds own 83.78% of the company’s stock.

Analyst Upgrades and Downgrades

YARW has been the subject of a number of research analyst reports. BTIG Research began coverage on Yarrow Bioscience in a report on Monday, August 3rd. They set a “buy” rating and a $58.00 price target for the company. TD Cowen assumed coverage on Yarrow Bioscience in a research note on Tuesday, July 28th. They issued a “buy” rating on the stock. Finally, Wall Street Zen upgraded Yarrow Bioscience to a “hold” rating in a research report on Saturday, August 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Yarrow Bioscience has a consensus rating of “Hold” and a consensus target price of $58.00.

Yarrow Bioscience Stock Performance

Shares of NASDAQ:YARW opened at $30.21 on Monday. Yarrow Bioscience has a 52 week low of $14.02 and a 52 week high of $46.95. The firm has a market cap of $80.66 million, a PE ratio of -2.06 and a beta of 2.01.

Yarrow Bioscience (NASDAQ:YARW) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($3.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($3.33). The company had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.20 million. Yarrow Bioscience had a negative net margin of 4,726.21% and a negative return on equity of 84.40%.

Yarrow Bioscience Announces Dividend

The business also recently declared a special dividend, which was paid on Thursday, July 23rd. Stockholders of record on Wednesday, July 22nd were paid a $19.00 dividend.

Yarrow Bioscience Profile

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.